Every 10-Q that LENZ Therapeutics, Inc. (LENZ) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow LENZ and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full LENZ filings page.
LENZ Therapeutics, Inc. reported its first full periods of commercialization for VIZZ, its FDA‑approved eye drop for presbyopia. For the three months ended June 30, 2026, revenue was $5.5 million, including $1.7 million of VIZZ product sales and $3.8 million of license revenue from ex‑U.S. partnerships.
The company recorded a quarterly net loss of $31.9 million and a six‑month net loss of $73.4 million, driven largely by selling, general and administrative expenses of $84.3 million for the first half as commercial activities expanded. Research and development expenses were minimal as major trials had been completed.
As of June 30, 2026, cash, cash equivalents and marketable securities totaled $220.0 million, total assets were $236.6 million, and stockholders’ equity was $219.3 million. The company had an accumulated deficit of $300.5 million but believes existing liquidity will fund operations for at least 12 months.
LENZ Therapeutics reported its first quarter of meaningful commercial activity for VIZZ, generating $1.9 million in total revenue for the three months ended March 31, 2026, including $1.7 million of net product sales and $0.25 million of license revenue.
The company posted a net loss of $41.5 million, compared with $14.6 million a year earlier, as selling, general and administrative expenses rose to $45.0 million with the U.S. launch and direct-to-consumer marketing, while research and development spending declined to zero after FDA approval of VIZZ.
LENZ ended the quarter with $258.4 million in cash, cash equivalents and marketable securities and total stockholders’ equity of $246.5 million, and used $33.6 million of cash in operating activities as it invested heavily in commercial infrastructure.
LENZ Therapeutics (LENZ) reported Q3 2025 results and highlighted FDA approval of VIZZ. The company recorded $12.5 million in license revenue in the quarter and $17.5 million year-to-date. Operating expenses rose with commercialization activities, led by selling, general and administrative of $27.6 million and research and development of $3.8 million, resulting in a net loss of $16.7 million (basic and diluted loss per share of $0.59).
LENZ ended September 30, 2025 with $202.2 million in cash, cash equivalents, and marketable securities and reported 28,540,519 weighted‑average shares outstanding for the quarter. The company sold 920,500 shares via its at‑the‑market program during the nine months ended September 30, 2025 for $26.1 million in net proceeds, and subsequently sold 2,698,134 shares in October at a weighted‑average price of $45.79. On July 31, 2025, the FDA approved VIZZ (aceclidine ophthalmic solution) 1.44% for presbyopia in adults.